Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent

Nuclear Medicine and Biology

Volumn 37, Issue 2, 2010, Pages 215-226

  Máthé, Domokos ^a   Balogh, Lajos ^a   Polyák, András ^a   Király, Réka ^a   Márián, Teréz ^b   Pawlak, Dariusz ^c   Zaknun, John J ^d   Pillai, Maroor R A ^d   Jánoki, Gyozo A ^a  

^a Department of Applied Radiopharmaceuticals   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

^d INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

Author keywords

Animal studies; Bone seeking radiopharmaceuticals; In vivo biodistribution; Radionuclide therapy; Small animal imaging

Indexed keywords

DIAMINE N,N,N',N' TETRAKIS(METHYLENE PHOSPHONIC ACID) LU 177; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BONE PAIN; BONE REMODELING; CANCER PALLIATIVE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOG; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PURITY; DRUG UPTAKE; IMAGE ANALYSIS; IN VIVO STUDY; MOUSE; NONHUMAN; RABBIT; RADIOCHEMISTRY; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKELETON; SPECIES DIFFERENCE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; URINARY EXCRETION;

ANIMALS; BONE AND BONES; DOGS; MALE; MICE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PALLIATIVE CARE; RABBITS; RATS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 76949107894     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.09.004     Document Type: Article

References (40)

1. Mercadante S., and Fulfaro F. Management of painful bone metastases. Curr Opin Oncol 19 (2007) 308-314
2. Cicek M., and Oursler M.J. Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev 25 (2006) 635-644
3. Berenson J.R., Rajdev L., and Broder M. Managing bone complications of solid tumors. Cancer Biol Ther 9 (2006) 1086-1089
4. Macedo A., Araujo A., Carvalho Melo F., et al. Cost-effectiveness of samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal. Acta Med Port 19 (2006) 421-426
5. Knapp F.F., Mirzadeh S., Beets A.L., et al. Reactor produced radioisotopes from ORNL for bone pain palliation. Appl Radiat Isot 49 (1998) 309-315
6. Anderson M.P., Wiseman A.G., Dispenzieri A., et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of systemic irradiation in patients with osteosarcoma and skeletal metastases. J Clin Onc 20 (2002) 189-196
7. Bauman G., Charette M., Reid R., and Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. Radiother Oncol 75 (2005) 258-270
8. Liepe K., Runge R., and Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol 131 (2005) 60-66
9. 186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast. Q J Nucl Med Mol Imaging 50 (2006) 355-362
10. Silberstein E.B. Dosage and response in the radiopharmaceutical therapy of painful osseous metastases. J Nucl Med 37 (1996) 249-252
11. Srivastava S., and Dadachova E. Recent advances in radionuclide therapy. Semin Nucl Med 31 (2001) 330-341
12. Finlay I.G., Mason M.D., and Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 6 (2005) 392-400
13. Hosain F., and Spencer R.P. Radiopharmaceuticals for palliation of metastatic osseous lesions: Biologic and physical background. Semin Nucl Med. 22 (1992) 11-16
14. Pandit-Taskar N., Batraki M., and Divgi C.R. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45 (2004) 1358-1365
15. Sartor O. Overview of samarium Sm-153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol 6 Suppl 10 (2004) S3-S12
16. Sartor O., Reid R.H., Bushnell D.L., Quick D.P., and Ell P.J. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 109 (2007) 637-643
17. Coronado M., Redondo A., Coya J., et al. Clinical role of Sm-153-EDTMP in the treatment of painful bone metastatic disease. Clin Nucl Med 31 (2006) 605-610
18. Wang R.F., Zhang C.L., Zhu S.L., and Zhu M. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med Princ Pract 12 (2003) 97-101
19. Sartor O., Reid R.H., Hoskin P.J., et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63 (2004) 940-945
20. 153Sm-EDTMP in patients with metastatic bone disease. J Nucl Med 42 (2001) 230-236
21. 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model. J Nucl Med 48 (2007) 122-127
22. 188Re-ethylenediamine-N,N,N′,N′tetrakis(methylene phosphonic acid) as a potential agent for bone pain palliation. Nucl Med Commun 23 (2002) 75-83
23. Liepe K., Franke W.G., Kropp J., Koch R., Runge R., and Hliscs R. Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases. Nuklearmedizin 39 (2000) 146-151
24. Li S., Liu J., Zhang H., Tian M., Wang J., and Zheng X. Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med 26 11 (2001 Nov) 919-922
25. 177Lu for radionuclide therapy. Appl Radiat Isot 59 (2003) 109-118
26. Bernhardt P., Benjegård S.A., Kölby L., et al. Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Int J Rad Onc Biol Phys 51 (2001) 514-524
27. Syme A.M., Kirkby C., Riauka T.A., Fallone B.G., and McQuarrie S.A. Monte Carlo investigation of single cell beta dosimetry for intraperitoneal radionuclide therapy. Phys Med Biol 49 (2004) 1959-1972
28. 177Lu-EDTMP: a potential therapeutic bone agent. Nucl Med Comm 19 (1998) 587-591
29. Rutty Solá A.G., Arguelles M.G., Botazzini D., et al. Lutetium-177 EDTMP for bone pain palliation. Preparation, biodistribution and pre-clinical studies. Radiochim Acta 88 (2000) 157-161
30. 177Lu-labeled polyaminophosphonates as potential agents for bone pain palliation. Nucl Med Commun 23 (2002) 67-74
31. 177Lu labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl. Radiat. Isot 57 (2002) 177-184
32. 177Lu-DOTMP: a viable agent for palliative radiotherapy of painful bone metastasis. Radiochim Acta 96 (2008) 55-61
33. 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis. Cancer Biother. Radiopharm. 23 (2008) 202-213
34. Sagar V.V., Piccone J.M., and Charkes N.D. Studies of skeletal tracer kinetics: III. Tc-99m(Sn)methylenediphosphonate uptake in the canine tibia as a function of blood flow. J Nucl Med 20 (1979) 1257-1261
35. 99mTc-medronate for bone imaging?. Nucl Med Commun 28 (2007) 101-107
36. 18F-fluoride on osteoblasts. Eur J Nucl Med Mol Imaging. 33 (2006) 491-494
37. 153Sm-ethylenediaminetetramethylene phosphonate in juvenile rabbit tibia: implications for targeted radiotherapy of osteosarcoma. J Nucl Med 46 (2005) 2076-2082
38. 153Sm-ethylenediaminetetramethylene phosphonate on physeal and articular cartilage in juvenile rabbits. J Nucl Med 44 (2003) 1510-1515
39. Eary J.F., Collins C., Stabin M., et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 34 (1993) 1031-1036
40. 186Re-HEDP. J Nucl Med 44 (2003) 247-251